Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse
11th December 2015
At the European Cancer Congress (ECC) 2015, Paul Nathan, MB.BS, BSc (Hons), BA, PhD, FRCP, of Mount Vernon Cancer Centre, Northwood, UK, discusses a study that was designed to determine whether seropositivity to a panel of tumour antigens was associated with a risk of relapse in patients with stage II and III melanoma.
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?
Keep your finger on the pulseJoin Now
Elevating the Quality of Healthcare Globally